Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2020-07-01
Edice:	Endocrinology, Diabetes & Metabolism
Témata:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
On-line přístup:	https://doi.org/10.1002/edm2.159
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!